Herzog, Samuel
Shanahan, Marian
Grimison, Peter
Tran, Anh
Wong, Nicole
Lintzeris, Nicholas
Simes, John
Stockler, Martin
Morton, Rachael L. http://orcid.org/0000-0001-7834-0572
Funding for this research was provided by:
National Health and Medical Research Council (1054216)
Cancer Australia (1129568)
Article History
First Online: 2 September 2017
Compliance with Ethical Standards
:
: No funding was received for this study.
: Samuel Herzog has no conflicts of interest. Marian Shanahan has no financial conflicts of interest. She has research interests in the economics of cannabis policies, and is leading an economic evaluation alongside an RCT of cannabinoid replacement therapy for the management of treatment-resistant cannabis-dependent patients. Peter Grimison is the principal investigator of a randomised, double-blind, placebo-controlled trial evaluating an oral THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting, which is funded by government body NSW Health, with drug supply by Tilray. Anh Tran has no conflicts of interest. Nicole Wong has no financial conflicts of interest. She is the project manager of an RCT evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting. Nicholas Lintzeris has received research grants from the Australian NHMRC, and the government body NSW Health, for randomised trials into cannabis-based medicines. He is an academic lead for the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, Australia; a co-investigator of an RCT evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting, and an RCT of cannabinoid replacement therapy for the management of treatment-resistant cannabis-dependent patients. John Simes has no financial conflicts of interest. He is a co-investigator of an RCT evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting. Martin Stockler has no financial conflicts of interest. He is a co-investigator of an RCT evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting. Rachael L. Morton has no financial conflicts of interest. She is leading an economic evaluation alongside an RCT evaluating an oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting.